Novavax, Inc.

Working closely with the Finance Committee, this committee provides crucial analysis and 'revenue estimates' for all tax legislation. Its technical expertise and reports directly influence corporate tax structures, R&D credits, and the overall tax burden on a company like Novavax, significantly impacting its financial outlook.

This committee controls taxation, trade, and entitlement spending (e.g., Medicare, Medicaid). Decisions on corporate tax policy, drug pricing within Medicare, and international trade agreements directly impact Novavax's profitability, market access, and overall financial valuation.

This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for health programs (e.g., CDC, NIH), scientific research, and vaccine procurement, directly impacting potential government contracts and R&D grants for Novavax.

This committee directly regulates the FDA (responsible for drug and vaccine approvals) and the NIH (a major source of research funding). It directly impacts drug approval oversight, clinical trial processes, and funding for pharmaceutical and biotech R&D, making it critically relevant to Novavax.

This committee oversees intellectual property laws, which are critical for protecting patents and innovations in biological product manufacturing. It also handles antitrust laws, influencing M&A activity and competitive practices that could directly affect Novavax's market position and strategy.

This committee oversees the Department of Defense and authorizes the NDAA. Funding for biodefense programs, pandemic preparedness, and R&D into biological countermeasures or military medical needs can directly impact revenue streams and R&D opportunities for a biological product manufacturer like Novavax.

This committee's funding decisions directly impact government healthcare contractors and medical device manufacturers. Novavax, as a biological product manufacturer, could be a direct supplier to the Department of Veterans Affairs, making this committee's actions highly relevant to potential revenue streams.

Members receive classified briefings on global threats, including potential biological or pandemic risks. Non-public information on such threats would be highly material to a vaccine and biological product developer like Novavax, creating a significant risk of informational asymmetry.

This committee regulates government procurement and efficiency. As a manufacturer of biological products (vaccines), Novavax is highly likely to engage in federal contracting, particularly for public health initiatives. Committee members would possess direct information about government procurement strategies and funding for such contracts.